First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer
暂无分享，去创建一个
U. Banerji | J. Spicer | D. Josephs | C. Twelves | D. Pinato | S. Blagden | R. Riisnaes | A. Zivi | K. Swales | A. Anthoney | C. Stavraka | K. Noguchi | L. Pope | S. Decordova | R. Shiokawa | J. Prince | K. Jones | M. Inatani | Aurelius Olmin | Rie Shiokawa